The Alliance for Clinical Trials in Oncology activated the QUANTUM trial (Alliance A062401) to evaluate a bispecific immunotherapy approach in primary plasma cell leukemia, a rare and highly aggressive blood cancer. The activation reflects continued efforts to develop targeted immune therapies in ultra-rare indications where enrollment can be especially challenging and where accelerated clinical progress depends on multi-site trial readiness.